Search for a trial

Chemoprophylaxis and Plasmodium falciparum NF54 sporozoite immunization challenged by heterologous infection

Primary objective: To determine whether CPS-immunization with NF54 Plasmodium falciparum parasites provides protection against challenge with the genetically distinct P. falciparum clones, NF135.C10 or NF166.C8.Secondary objectives:• To investigate…

Controlled Human Malaria Infection after bites from mosquitoes infected with NF135.C10 or NF166.C8 Plasmodium falciparum parasites

Primary Objective: To assess the proportion of volunteers who develop parasitemia after Controlled Human Malaria Infection with bites from one, two or five NF166.C8- or NF135.C10-infected mosquitoes.Secondary Objectives: To assess kinetics of…

Immunization with different numbers of Plasmodium falciparum infected mosquito-bites under chloroquine prophylaxis

Primary Objective: To determine if two thirds or one third of the CPS immunization dose still induces complete protection against an experimental malaria challenge. Secondary Objectives: • To study and compare parasitemia and kinetics of parasitemia…

Comparison of three Plasmodium falciparum isolates in an experimental human malaria infection

• Primary objective (parasitological): To investigate the kinetics of parasitemia of different Plasmodium falciparum isolates• Secondary objective (immunological): To investigate parasite development and immunological properties of different…

Immunization with Plasmodium falciparum sporozoites under chloroquine versus mefloquine prophylaxis

Primary Objective: To compare protection against controlled Plasmodium falciparum malaria infection after immunization with sporozoites under chloroquine with immunization under mefloquine prophylaxis. Secondary Objectives: • To study and compare…

Comparison of three Plasmodium falciparum isolates in a controlled human malaria infection

Primary objective (parasitological): To investigate the parasitaemic kinetics of three different Plasmodium falciparum isolates (NF54, NF135 and NF166) during a controlled human malaria infection.Secondary objective (parasitological, clinical and…

A two-part, randomized, double-blind, placebo-controlled, single-center study to evaluate the safety and causal prophylactic efficacy of KAF156 in a controlled human malaria challenge model

This is a two part proof of efficacy study of KAF156 as a causal prophylactic agent in malaria. Results will be used to guide dose selection for further development of KAF156 in patients.

Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteers

Phase 1 • Primary objective: to determine the safety and tolerability, including the attenuation phenotype of a novel late-arresting GAP, named GA2 parasite, administered by sequentially increasing numbers of mosquito bites.• Secondary objective: to…

Coadministration of genetically attenuated Plasmodium falciparum *mei2 (GA2) sporozoites with adjuvants - a proof of principle study

This study has been transitioned to CTIS with ID 2024-516488-99-00 check the CTIS register for the current data. Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-…

Safety and protective efficacy of genetically attenuated Pf*b9*slarp (PfSPZ-GA1) malaria parasites in healthy volunteers

The study is divided in Stage A and BGA1 stage A1. To determine the safety and tolerability of direct venous inoculation of PfSPZ-GA1 in healthy volunteers.GA1 stage B Primary objective:1. To determine the safety, and tolerability of PfSPZ-…